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The World Health Organization estimates that lower respiratory tract (LRT) infection 25 
is the most common infectious cause of death worldwide and the fourth most 26 
common cause overall, with 3 million deaths attributed to LRT infection in 2016 [1]. 27 
Timely and reliable identification of the underlying pathogen is critical for initiating 28 
effective and tailored antimicrobial treatment, but identifying the microbial etiology of 29 
pneumonia is challenging in many clinical settings. Community-acquired pneumonia 30 
(CAP) is an acute infection of the lung parenchyma acquired outside hospital or 31 
healthcare facilities. Microbiological testing to attempt an etiological diagnosis is 32 
generally recommended for CAP patients requiring hospitalization [2, 3]. 33 
 34 
The “gold standard” for determining pneumonia etiology is the detection of respiratory 35 
pathogens in specimens taken directly from the site of infection, the lungs, by 36 
bronchoalveolar lavage (BAL), pleural fluid sampling, or lung biopsy [4]. Sputum and 37 
tracheal aspirates are LRT specimens with a higher probability of upper respiratory 38 
tract (URT) contamination. Because BAL, pleural fluid sampling, and lung biopsy are 39 
invasive procedures, they are rarely performed in clinical practice. Therefore, the 40 
etiological diagnosis of CAP mostly depends on the detection of respiratory 41 
pathogens from specimens distant to the site of infection, such as URT samples, 42 
blood, and urine. Current recommendations for routine diagnostic testing in adult 43 
CAP patients include sputum Gram stain and culture, blood cultures, and urinary 44 
antigen tests for Legionella pneumophila and Streptococcus pneumoniae 45 
(pneumococcus) [2]. In children, sputum collection is hampered by difficulties with 46 
expectoration, and urinary pneumococcal antigen tests are not recommended. 47 
Testing for influenza virus, other respiratory viruses, and Mycoplasma pneumoniae in 48 
URT specimens by polymerase chain reaction (PCR) and/or rapid antigen tests may 49 




Recent large-scale studies performed extensive microbiological testing to determine 52 
the etiology of pneumonia in hospitalized adults (Musher et al. [5], U.S., n=215; CDC 53 
EPIC study [6], U.S., n=2,259; Gadsby et al. [7], U.K., n=323; CAPiTA study [8], the 54 
Netherlands, n=1,653) and children (CDC EPIC study [9], U.S., <18 years old, 55 
n=2,222; Drakenstein Child Health study [10], South Africa, <2 years old, n=284; 56 
PERCH study [11], Africa and Asia, <5 years old, n=1,769) with a positive chest 57 
radiograph. A viral or bacterial pathogen was detected in 81–99% of pediatric and 58 
38–45% of adult CAP cases, except Gadsby et al. [7] reported a high detection rate 59 
in adults of 87%. Viruses accounted for the majority of detected pathogens [6, 7, 9-60 
11], particularly in young children (>90%) [10]. Both viral and bacterial pathogens 61 
were detected in up to 90% of children [9-11], but <10% of adult patients [5, 6, 8]. 62 
Conjugate vaccines have successfully reduced the burden of the former main causes 63 
of pneumonia, S. pneumoniae and Haemophilus influenzae type b, over the past 64 
three decades. M. pneumoniae is now the most commonly detected bacterial 65 
pathogen in children hospitalized with CAP in the U.S. [9]. 66 
 67 
Test results and epidemiological data must be carefully interpreted as no single 68 
diagnostic method applied to non-pulmonary specimens has both high sensitivity and 69 
high specificity for determining pneumonia etiology. Blood cultures are insensitive 70 
because they are positive in less than one-third of suspected bacterial pneumonia 71 
cases [5, 6, 8-11], but they are highly specific in determining pneumococcal 72 
pneumonia. In contrast, whole blood PCR and urinary antigen tests exhibit poor 73 
specificity, as they are also positive in patients who carry S. pneumoniae in the URT 74 
[11]. S. pneumoniae can be detected in the URT of up to 77% and 34% of healthy 75 
children and adults, respectively [11, 12]. In addition, S. pneumoniae carriage elicits 76 
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systemic antibody responses to pneumococcal antigens, limiting antibody detection 77 
as a diagnostic test to reliably determine pneumonia etiology [13]. This may also be 78 
true for M. pneumoniae, the detection of which by PCR in URT specimens and 79 
serology is not able to differentiate between infection and carriage [14]. Furthermore, 80 
the detection of many potential pathogens in the URT of a CAP patient represents 81 
carriage, URT infection, asymptomatic infection, or persistence of the pathogen after 82 
infection [11]. This complicates the assignment of causative pathogens in the URT 83 
for the pneumonia episode. In the PERCH study [11], more than half of childhood 84 
pneumonia cases (59%) and controls (54%) had ≥4 pathogens detected by multiplex 85 
PCR in URT specimens. Only RSV and Bordetella pertussis were rarely detected in 86 
URT specimens from healthy controls [10, 11]. 87 
 88 
Sputum has advantages in determining pneumonia etiology, including its origin from 89 
the LRT and non-invasive collection. Sputum induction, such as through hypertonic 90 
saline nebulization, may increase the likelihood of obtaining a valid sample and is 91 
especially useful in young children who are unable to expectorate spontaneously. 92 
Interestingly, testing of induced sputum is more sensitive than testing URT samples 93 
for the detection of several CAP pathogens in young children [10]. 94 
 95 
In this issue of Clinical Infectious Diseases, Ogawa et al. present a rigorous 96 
systematic review and meta-analysis of the literature on the diagnostic accuracy and 97 
yield of sputum Gram stain for diagnosing a bacterial pathogen in CAP [15]. Twenty-98 
four studies were included (n=4,533 adults), 22 on diagnostic accuracy and 4 on the 99 
diagnostic yield of this method. Consistent with previous studies, though on a larger 100 
scale, these new results suggest that Gram stain performed on good-quality sputum 101 
is highly specific for the diagnosis of S. pneumoniae and H. influenzae infections in 102 
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adult CAP patients (point estimates 0.91 and 0.97, respectively). Good-quality 103 
sputum was defined as the presence of <10 squamous epithelial cells and >25 104 
polymorphonuclear cells per low-power field [16, 17]. Data on other bacteria were 105 
limited. Sputum Gram stain diagnosed the bacterial pathogens in 36% of patients 106 
when sputum samples were collected successfully, increasing to 73% if only good-107 
quality sputum samples were selected. 108 
 109 
This study has three major strengths. First, the analyses were performed on studies 110 
with sputum Gram stain of good-quality samples. The applied sputum quality criteria 111 
may have helped detect URT contamination [16]. Second, the different (composite) 112 
reference standard tests of studies included in the work were extracted thoroughly 113 
and considered. This is essential, as BAL, pleural fluid sampling, and lung biopsy 114 
were rarely available, and the reference standard test (usually sputum culture) was 115 
imperfect in most cases. Third, the meta-analysis was performed using the Bayesian 116 
latent-class model, which accounts for the multiple imperfect reference standards. 117 
The study’s major limitations are variations between included studies regarding pre-118 
test symptoms and treatment, sample collection, transport, and processing methods, 119 
as well as the interpretation of results. Therefore, failure to detect pathogens on 120 
sputum Gram stain does not necessarily prove their absence. However, summary 121 
estimates across different subgroup analyses were consistent with those of the main 122 
analysis, and the major findings were confirmed by another recent review [18]. 123 
 124 
The results of this meta-analysis support current guidelines recommending prompt 125 
examination of pre-treatment sputum Gram stain and culture in hospitalized adults 126 
with CAP if good-quality specimens can be obtained and quality performance 127 
measures met [2]. Sputum Gram stain can be clinically useful in narrowing standard 128 
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(empirical) treatment decisions by providing immediate information about the 129 
potential causative pathogens, and sputum culture may enable pathogen isolation for 130 
sensitivity testing, which is the most important issue for many patients. Future studies 131 
on sputum Gram stain may focus on the possibility and consequences of URT 132 
contamination of even good-quality sputum and further elaboration of the diagnostic 133 
utility of induced sputum in children [10, 19-21]. 134 
 135 
Progress has been made towards determining the etiology and pathophysiology of 136 
pneumonia in recent years. Future challenges facing pneumonia etiology research 137 
include assigning a causative agent(s) from multiple potential pathogens detected in 138 
the URT during a pneumonia episode (even more so in children than adults), 139 
improving the pathogen-detection yield in adults, and tackling the pathophysiological 140 
significance of the lung microbiome, including putative pneumonia pathogens, 141 
moving away from a single-pathogen perspective [22, 23]. This can only be achieved 142 
with improved diagnostic methods. Thus, we need to advance current testing 143 
methods while exploring new and innovative approaches. Such an innovative and 144 
minimally invasive approach may be the detection of pathogen-specific antibody-145 
secreting cells (Figure 1) [24], which allow differentiation between M. pneumoniae 146 
infection and carriage in children with CAP [14]. Other promising diagnostic 147 
approaches are exhaled breath analysis [25], novel biomarkers [26], new point-of-148 
care and antigen detection assays [27], multidimensional (molecular) assessment of 149 
the host response [28], and new analytical approaches [11]. Efforts to determine the 150 
microbial etiology and understand the complex pathophysiology of pneumonia are 151 
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Figure 1. Pneumonia pathophysiology and testing methods. A: Chest radiograph 251 
of a child with CAP. The pulmonary infiltrate is indicated by the frame. B: Schematic 252 
representation of the possible pathophysiology of childhood pneumonia. C: Overview 253 
of different specimens and testing methods for pneumonia diagnostics. 254 
Abbreviations: ASC, antibody-secreting cell; BAL, bronchoalveolar lavage; ELISA, 255 
enzyme-linked immunosorbent assay; ELISpot, enzyme-linked immunospot; LRT, 256 
lower respiratory tract; PCR, polymerase chain reaction; URT, upper respiratory tract. 257 
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